Celldex share decline an overreaction, says Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska tells investors that shares of Celldex (CLDX) have declined 28% over the last six months primarily driven by concerns around safety, which the firm believes to be an overreaction. The chronic spontaneous urticaria trials are now in Phase 3 execution mode, and there is unlikely to be any data in 2025, Cantor says, adding that while there should be data from other indications, recent analyses work suggests buying stocks 12-18 months in advance holds the best potential return. Cantor has an Overweight rating and $67 price target on Celldex shares.